Juan Tamargo
Tamargo, Juan
VIAF ID: 373148996233859752931 (Personal)
Permalink: http://viaf.org/viaf/373148996233859752931
Preferred Forms
- 100 0 _ ‡a Juan Tamargo
-
4xx's: Alternate Name Forms (7)
Works
Title | Sources |
---|---|
Glucuronidated quercetin lowers blood pressure in spontaneously hypertensive rats via deconjugation. | |
Group B Streptococcus and E. coli LPS-induced NO-dependent hyporesponsiveness to noradrenaline in isolated intrapulmonary arteries of neonatal piglets | |
Guía ESC 2017 sobre el diagnóstico y tratamiento de la enfermedad arterial periférica, desarrollada en colaboración con la European Society for Vascular Surgery (ESVS) | |
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology | |
The HERACLES Cardiovascular Network | |
Hypertension magnitude and management in the elderly population of Spain | |
The impact of new and emerging clinical data on treatment strategies for atrial fibrillation | |
In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both | |
The mechanism of the positive inotropic action of ketamine on isolated atria of the rat. | |
Mechanisms by which calcium modulates diastolic depolarization in sheep cardiac Purkinje fibers | |
Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. | |
Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients | |
mu- and delta-opioid receptor-mediated contractile effects on rat aortic vascular smooth muscle | |
Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. | |
Nav1.5 N-terminal domain binding to α1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels | |
Negative inotropic effect of somatostatin in guinea-pig atrial fibres | |
New insights in the pharmacological therapy of arterial hypertension | |
New investigational drugs for the management of acute heart failure syndromes. | |
Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism. | |
Nitric oxide increases cardiac IK1 by nitrosylation of cysteine 76 of Kir2.1 channels. | |
Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1). | |
Nitric oxide (NO) scavenging and NO protecting effects of quercetin and their biological significance in vascular smooth muscle. | |
Novel therapeutic targets for the treatment of heart failure. | |
Old and new molecular mechanisms associated with platelet resistance to antithrombotics | |
Optimization of beta-blockers' pharmacology. | |
p.D1690N Nav1.5 rescues p.G1748D mutation gating defects in a compound heterozygous Brugada syndrome patient | |
Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes | |
Pharmacology of cardiac potassium channels. | |
Pharmacology of CRE-1087, A New Antiarrhythmic Drug | |
PITX2 insufficiency leads to atrial electrical and structural remodeling linked to arrhythmogenesis | |
Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing IKs and decreasing ICa,L. | |
Plasma desmoplakin I biomarker of vascular recurrence after ischemic stroke. | |
Platelet content of nitric oxide synthase 3 phosphorylated at Serine 1177 is associated with the functional response of platelets to aspirin. | |
Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. | |
Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore. | |
Propafenone modulates potassium channel activities of vascular smooth muscle from rat portal veins. | |
Propafenone preferentially blocks the rapidly activating component of delayed rectifier K+ current in guinea pig ventricular myocytes. Voltage-independent and time-dependent block of the slowly activating component. | |
Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. | |
Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome. | |
Proteomic Study of Plasma from Moderate Hypercholesterolemic Patients | |
Pulmonary versus systemic effects of vasodilator drugs: an in vitro study in isolated intrapulmonary and mesenteric arteries of neonatal piglets | |
Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). | |
Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats | |
Ranolazine: an antianginal drug with antiarrhythmic properties | |
Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase | |
The Renin–Angiotensin System and Bone | |
Respuesta | |
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular | |
Role of K+ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways | |
Role of Reactive Oxygen Species in Kv Channel Inhibition and Vasoconstriction Induced by TP Receptor Activation in Rat Pulmonary Arteries | |
Role of UCP2 in the protective effects of PPARβ/δ activation on lipopolysaccharide-induced endothelial dysfunction. | |
The safety of digoxin as a pharmacological treatment of atrial fibrillation. | |
Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization | |
Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. | |
Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels | |
Stanowisko ESC dotyczące toksycznego wpływu leczenia onkologicznego na układ sercowo-naczyniowy w 2016 roku, opracowane pod auspicjami Komisji ESC do spraw Wytycznych Postępowania | |
Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes | |
Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5) | |
Stereoselective effects of the enantiomers, quinidine and quinine, on depolarization- and agonist-mediated responses in rat isolated aorta | |
Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents. | |
Structural determinants of potency and stereoselective block of hKv1.5 channels induced by local anesthetics. | |
Tbx20 controls the expression of the KCNH2 gene and of hERG channels | |
TGF 3 mutations cause arrhythmogenic right ventricular dysplasia type 1 and open the door to understanding the biological role of TGF 3 (where there's a will, there's a way): EXPERT'S PERSPECTIVE | |
Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Czeta. | |
Tonic and frequency-dependent Vmax block induced by imipramine in guinea pig ventricular muscle fibers | |
Treatment of left ventricular hypertrophy in hypertensive patients. | |
Unresolved issues in the management of chronic stable angina | |
An update on atrial fibrillation in 2014: From pathophysiology to treatment. | |
Vascular superoxide production by endothelin-1 requires Src non-receptor protein tyrosine kinase and MAPK activation. | |
Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships | |
Vasorelaxant effects of the bioflavonoid chrysin in isolated rat aorta | |
Ventricular tachycardia in a patient with congenital coronary arteriovenous fistula | |
Voltage- and time-dependent inhibitory effects on rat aortic and porcine coronary artery contraction induced by propafenone and quinidine |